

CAPABILITY STATEMENT

Mission: Combatting the Global Rise of Antibiotic Resistant Bacterial Infection

MEMSEL INTRODUCTION

At the Forefront of Biotechnology Innovation, Spearheading the Advancement of Health and Infection Therapeutics. Revolutionizing Care with Cutting-Edge Phage Therapies and Precision Delivery Systems.







Memsel TraumaCare360:

Phage-Enhanced Polytrauma Wound Management System for Prolonged Field Care in Multi-Domain Operations

Injectable and Spray-On Gauze Applications: comprehensive, easy to use solutions for managing complex wound conditions.

Multicomponent Formulation:

Stop Bleeding: rapid hemostasis

Tissue Healing: accelerate tissue repair

Pain Control: controlled release of

analgesics

Broad Bacterial Infection Prevention: Antibiotics for broad bacterial infection prevention

Antibiotic-Resistant Infection Prevention: Phage cocktails effective against multiple, high priority pathogens: *Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus*

Fungal & Biofilm Infection Prevention: Antifungal and biofilm prevention agents.







Stop Bleeding | Prevent Infection | Accelerate Wound Healing | Save Lives

www.memsel.com



CAPABILITY STATEMENT

Vision: A World Without Infection Multi-Functional Formulations and Phage Therapy

TRACTION

Defense Health Agency (DHA) STTR Program

Preventing multi-drug resistant bacteria infection with stabilized bacteriophages incorporated into Memsel Point of Need formulation



Domestic Preparedness Support Initiative (DPSI)

Supporting DPSI mission to transfer Memsel TraumaCare360™ to Federal, State, and local first responder communities



Naval Energetic Systems and Technologies (NEST) OTA, in partnership with the National Armaments Consortium (NAC)

NEST RPP: Advanced Biological Defeat Trauma System, CBRN-23-C-001 OTA contract to advance the development of Memsel Advanced Trauma System to Improve Warfighter Readiness





CORPORATE PROFILE

HEADQUARTERS

University North Texas Health Science Center 3500 Camp Bowie Blvd., EAD-116, Fort Worth, Texas, 76107

PRIMARY CONTACT: Thomas England, CEO

DIRECT PHONE: 713-408-3435

DIRECT EMAIL: thomas@memsel.com

CAGE: 8K2V7 **DUNS**: 117483592 **UEI**: MVL7NJZWLJ87 **DD2345**: 0085626

Set-Asides: Small Business

NAICS & PSC:

- 541713 R&D Nanotechnology
- 541714 R&D Biotechnology
- 541715 Research and Development in the Physical, Engineering, and Life Sciences
- 3391 Medical Equipment and Supplies Manufacturing

COLLABORATORS



OTA Consortia Memberships







www.memsel.com